These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17890885)

  • 1. EGFR inhibitors in the treatment of lung cancer.
    Hirsch FR
    Onkologie; 2007 Oct; 30(10):476. PubMed ID: 17890885
    [No Abstract]   [Full Text] [Related]  

  • 2. Erlotinib hydrochloride.
    Minna JD; Dowell J
    Nat Rev Drug Discov; 2005 May; Suppl():S14-5. PubMed ID: 15962526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents.
    Ghosn M; Assi T; El Rassy E; Moussa T; Kattan J
    Bull Cancer; 2017 Apr; 104(4):385-387. PubMed ID: 28131317
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
    Cappuzzo F
    J Natl Cancer Inst; 2005 Jun; 97(12):868-9. PubMed ID: 15956643
    [No Abstract]   [Full Text] [Related]  

  • 6. Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?
    Hirsch FR; Bunn PA
    J Clin Oncol; 2005 Dec; 23(36):9044-7. PubMed ID: 16301593
    [No Abstract]   [Full Text] [Related]  

  • 7. Treating non-small-cell lung cancer first line with erlotinib monotherapy in elderly patients: discussion of a case series.
    Reck M
    Onkologie; 2007 Oct; 30(10):515-8. PubMed ID: 17890891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib.
    Kuiper JL; Heideman DA; Thunnissen E; van Wijk AW; Postmus PE; Smit EF
    Eur J Cancer; 2014 May; 50(7):1399-401. PubMed ID: 24582911
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting EGFR in non-small-cell lung cancer.
    Doroshow JH
    N Engl J Med; 2005 Jul; 353(2):200-2. PubMed ID: 16014890
    [No Abstract]   [Full Text] [Related]  

  • 10. Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
    Pirl WF; Solis J; Greer J; Sequist L; Temel JS; Lynch TJ
    J Clin Oncol; 2009 Aug; 27(23):e49-50; author reply e51. PubMed ID: 19597022
    [No Abstract]   [Full Text] [Related]  

  • 11. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 12. Epidermal growth factor receptor inhibitors in non-small cell lung cancer.
    Dancey JE
    Drugs; 2007; 67(8):1125-38. PubMed ID: 17521215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
    Gridelli C; Maione P; Amoroso D; Baldari M; Bearz A; Bettoli V; Cammilluzzi E; Crinò L; De Marinis F; Di Pietro FA; Grossi F; Innocenzi D; Micali G; Piantedosi FV; Scartozzi M
    Crit Rev Oncol Hematol; 2008 May; 66(2):155-62. PubMed ID: 18083041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
    Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
    Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What new therapeutic targets exist for EGFR-mutant NSCLC?
    Rosell R
    Lancet Oncol; 2014 Oct; 15(11):1184-5. PubMed ID: 25175098
    [No Abstract]   [Full Text] [Related]  

  • 16. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
    Chin TM; Quinlan MP; Singh A; Sequist LV; Lynch TJ; Haber DA; Sharma SV; Settleman J
    Clin Cancer Res; 2008 Nov; 14(21):6867-76. PubMed ID: 18980981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Riely GJ
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S146-9. PubMed ID: 18520300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Erlotinib in non-small cell lung cancer].
    Takeda M; Okamoto I
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):896-900. PubMed ID: 21677478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
    Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
    Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.